4 November 2024

NIVI attending the World Vaccine Congress 2024

Vaccines

Thousands of vaccine experts have just been gathered for the The World Vaccine Congress in Barcelona – including three of our NIVI team members - Kara-Lee Aves, Mike Whelan and Niels Thulstrup.

NIVI team members
NIVI team members at the World Vaccine Congress 2024 (left to right): Chief Business Officer, Niels Thulstrup, Director, External R&D Kara-Lee Aves and Head of the Project Management Office, Mike Whelan.

During four great and inspiring days, the three NIVI  team members have been connecting and networking with the global vaccine industry, and hearing about the latest innovations and emerging trends in the field of vaccine technologies, infection models, manufacturing supply chains and global access.

Some of the teams favorite sessions at the WVC evolved around how to strengthening the global pandemic preparedness and the increasing need for non-traditional measurements and correlates of protection, which are also key to the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI).

The aim of the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) is to revolutionize and accelerate vaccine development by bridging the gap between academic research and industry innovation.

About NIVI

NIVI conducts basic and translational research with an emphasis on developing new vaccines targeting respiratory-route pathogens that have outbreak potential or that, directly or indirectly, promote the spread of antimicrobial resistance (AMR).

NIVI brings together leading experts in immunology and vaccine development from Denmark and around the world to develop vaccine candidates against some of the most important and deadly respiratory pathogens

NIVI is an initiative comprised of two distinct entities:

1) The Novo Nordisk Foundation Center for Vaccines and Immunity (NCVI)

NCVI strives to be a world-leading academic research center anchored at the Department of Immunology and Microbiology at the University of Copenhagen. NCVI directs the research, discovery and educational aspects of the NIVI initiative. 

For detailed information, please visit About NCVI.  

2) The Novo Nordisk Foundation Vaccine Accelerator (NVAC)

NVAC P/S is a limited liability company owned by the Novo Nordisk Foundation. NVAC enables the translational efforts of NIVI by providing industry-level expertise in vaccine development and conducting clinical studies (Phase 1 & 2, including CHIM) for new vaccine candidates. 

For detailed information, please visit the NVAC website

Topics